Oragenics Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Oragenics, Inc. on April 1, 2011. The filing reports a corporate governance event: the appointment of a new independent director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or operational metrics.
Material Changes
- Board Appointment: On April 1, 2011, the Board appointed Dr. Alan W. Dunton as a non-employee, independent director.
- Committee Assignment: Dr. Dunton was simultaneously appointed to the Audit Committee.
- Compensation: Dr. Dunton received options to acquire 5,000 shares of common stock at an exercise price of $3.30 (the closing price on April 1, 2011). He is also eligible for cash payments under the director compensation program.
Outlook, Risks, and Management Commentary
Management selected Dr. Dunton due to his extensive business and industry experience, including prior roles as CEO of Panacos Pharmaceuticals and Metaphore Pharmaceuticals, and his tenure as a director at Targacept, Inc. The Board determined he is independent and possesses the financial sophistication required for Audit Committee membership. No material relationships or conflicts of interest were disclosed.
Investor Verification Checklist
- Verify the independence status of Dr. Dunton regarding the Audit Committee rules.
- Confirm the terms of the 5,000 share option grant (exercise price $3.30) under the Company's Option Plan.
- Review the attached press release (Exhibit 99.1) for additional details on the appointment.
- Check subsequent filings for any changes to the Board composition or compensation plans.